Health Condition 1: null- Myeloproliferative neoplasms
Conditions
Interventions
None listed
Sponsors
Novartis Healthcare Pvt Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1. Male or female patients = 18 years of age who have been diagnosed with a Ph-MPN according to the 2008 revised World Health Organization criteria 2.Willing and able to provide written informed consent according to local guidelines prior to any study procedures 3. Have availability of historical medical records that verify diagnosis 4. Willing to complete and literate in the language of the available health related quality of life (HRQoL) instrument either alone or with minimal assistance from caregivers and/or trained site personnel
Exclusion criteria
Exclusion criteria: 1. According to the investigator?s opinion, the patient is an unlikely candidate to obtain longterm follow-up information for any reasons such as unavailability or severe concomitant illnesses 2. Patients with active alcohol or drug addiction that would interfere with their ability to comply with the study requirements 3. Patients with any concurrent condition that, in the Investigator?s opinion, would jeopardize the safety of the patient or compliance with the protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To describe the current diagnosis, treatment, pattern in ET, PV, and MF patients in routine clinical practiceTimepoint: Diagnosis, Treatment patterns (incidence, prevalence, drug therapy used, duration, reason for discontinuation, treatment dose adjustment) Sequencing/changes in therapies Reason/s to change treatment (including dose changes) Time to disease progression from baseline | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess the economic burden captured by medical resource utilizations using common reference units (e.g., number of hospital admissions and days in hospital)Timepoint: Change in frequency of resource utilization from baseline Change in frequency of resource utilization from current line of therapy to subsequent line of therapy;To describe patient QOL and the association of QOL with change of therapyTimepoint: QOL Change in QOL from baseline to change in therapy Change in QOL from current line of therapy to subsequent line of therapy | — |
Countries
Algeria, China, Hong Kong, India, Israel, Jordan, Kuwait, Lebanon, Malaysia, Pakistan, Philippines, Qatar, Republic of Korea, Singapore, Taiwan, Turkey, United Arab Emirates, Viet Nam
Contacts
Public ContactDr Manish Mistry
Novartis India Limited
Outcome results
None listed